PF
PFE
—
NYSE
Pharmaceuticals
Pfizer Inc
LatestPfizer Q1 Earnings Beat Estimates, Reaffirms 2026 Outlook
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
143,6B USD
P/E
18,2x
EV / Rev
3,3x
Div yield
6,87 %
Op margin
—
ROE
8,6 %
Net margin
12,4 %
Debt / equity
0,72
Beta
—
52w range
—
Volume
26
Day range
—
Prev close
$24,67
Open
$24,60
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
PFIZER INC is classified under Healthcare / Biotechnology and appears profitable on the latest normalized snapshot.
Business. Pfizer Inc. (PFE) is a pharmaceutical company headquartered in the United States that operates within the Healthcare sector. The firm is primarily listed on the New York Stock Exchange under the ticker symbol PFE. As a major player in the Pharmaceuticals industry, Pfizer engages in the research, development, and sale of pharmaceutical products. Specific details regarding its operating segments or geographic revenue mix are not provided in the available data.
Classification99 %
SectorHealth Care
Industry groupPharmaceuticals
Generated · rules-based
Sell-side consensus
HOLD32 analysts
11 buy19 hold2 sell
Avg 12m price target28,58
Analyst recommendations
32 analysts · consensus HoldBuy11
Hold19
Sell2
12-month price target
28,58
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation→
18,2x
P/E
Analysts→
Hold
32 analysts · indicative
Ownership→
Fisher Investments
largest disclosed fund holder
Profitability→
8,6 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
1Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to PFE. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
- Congressional trades
- CongressThomas H Tuberville — Pfizer, Inc. Common Stock2026-06-08 · Republican · AL · Sale · $15,001 - $50,000
- CongressLisa McClain — Pfizer, Inc. Common Stock2025-08-04 · Republican · MI · Sale · $1,001 - $15,000
- CongressLisa McClain — Pfizer, Inc. Common Stock2025-07-16 · Republican · MI · Purchase · $1,001 - $15,000
- CongressJosh Gottheimer — Pfizer, Inc. Common Stock2025-06-03 · Democrat · NJ · Sale · $1,001 - $15,000
- CongressJulie Johnson — Pfizer, Inc. Common Stock2025-02-12 · Democrat · TX · Sale · $1,001 - $15,000
- CongressJulie Johnson — Pfizer, Inc. Common Stock2025-01-15 · Democrat · TX · Sale · $1,001 - $15,000
Pre-earnings brief
Briefing · model-assisted
There are no material changes, watcher signals, or cross-source sentiment shifts to report for Pfizer Inc (PFE) in the provided data. The system indicates this is the first analysis for this ticker, meaning there is no prior basis for computing deltas or identifying specific changes in performance or market perception. The available data confirms Pfizer’s structural presence in the market, noting it is followed by 12 analysts and held by 36 top holders. The company maintains membership in one index and has one officer on record. These metrics establish a baseline of institutional interest and governance structure but do not indicate any recent volatility or strategic shifts. Cross-source signal data from late June through early July 2026 shows zero dispatches per day, with no associated sentiment values. This absence of news flow or analyst commentary during this period suggests a quiet phase in public reporting or market activity regarding the company. Without specific events, financial results, or rating changes cited in the facts, no further synthesis of "what changed" or "why it matters" can be constructed. The current snapshot reflects a static baseline rather than a dynamic period of change.
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Pfizer Inc. (PFE) is a pharmaceutical company headquartered in the United States that operates within the Healthcare sector. The firm is primarily listed on the New York Stock Exchange under the ticker symbol PFE. As a major player in the Pharmaceuticals industry, Pfizer engages in the research, development, and sale of pharmaceutical products. Specific details regarding its operating segments or geographic revenue mix are not provided in the available data.
Classification99 %
SectorHealth Care
Industry groupPharmaceuticals
AI synthesis
GENERATEDPFIZER INC (PFE) is currently classified as Biotechnology within Biotechnology (Healthcare). Classification confidence: 0.81 (rule-based classification). Capital structure on the latest snapshot: total assets 207,618,000,000 USD, total equity 90,101,000,000, short-term debt 3,861,000,000, long-term debt 60,565,000,000. Net cash position is approximately -62,723,000,000 USD. Self-calculated market cap is 141,613,010,000 USD (market_price × shares_outstanding_diluted). Profitability profile: revenue 14,451,000,000, gross profit 0, operating income 0, net income 2,687,000,000. Return on equity ~8.6%. Return on assets ~3.7%. Operating-cash-flow to net-income ratio is 1.51. Risk profile from automated assessment: liquidity risk high, dilution risk medium. Flags: Current ratio is close to the minimum comfort range.; Net cash is negative after subtracting total debt.; Source documents mention dilution or offering risk.. Recent news context: [TRIGGER] pre_earnings_window: pre_earnings_window (pre_earnings_window) on PFE — reason=Pre-earnings freshness window T-1 for PFE Q2 2026 (confirmed via fmp); urgency=high; watcher=pre_earnings_window; days_out=1; source_id=fmp:PFE:2026-08-04; date_basis=fmp_earnings_calendar; date_source=fmp; offset_days=1; report_date=2026-08-04; period_label=Q2 2026; window_label=T-1; eps_estimated=0.68; contributing_watchers=pre_earnings_window (source=fmp; url=pew:Q2 2026:T-1). Additional context: pre_earnings_window: reason=Pre-earnings freshness window T-1 for PFE Q2 2026 (confirmed via fmp); urgency=high; watcher=pre_earnings_window; days_out=1; source_id=fmp:PFE:2026-08-04; date_basis=fmp_earnings_calendar; date_source=fmp; offset_days=1; report_date=2026-08-04; period_label=Q2 2026; window_label=T-1; eps_estimated=0.68; contributing_watchers=pre_earnings_window. Management commentary signal: purchase the targeted number of shares on the date of executing the accelerated share repurchase agreement..
There are no material changes, watcher signals, or cross-source sentiment shifts to report for Pfizer Inc (PFE) in the provided data. The system indicates this is the first analysis for this ticker, meaning there is no prior basis for computing deltas or identifying specific changes in performance or market perception. The available data confirms Pfizer’s structural presence in the market, noting it is followed by 12 analysts and held by 36 top holders. The company maintains membership in one index and has one officer on record. These metrics establish a baseline of institutional interest and governance structure but do not indicate any recent volatility or strategic shifts. Cross-source signal data from late June through early July 2026 shows zero dispatches per day, with no associated sentiment values. This absence of news flow or analyst commentary during this period suggests a quiet phase in public reporting or market activity regarding the company. Without specific events, financial results, or rating changes cited in the facts, no further synthesis of "what changed" or "why it matters" can be constructed. The current snapshot reflects a static baseline rather than a dynamic period of change.
Key takeaways
- Observed GAAP P/E is about 18.22x.
- Return on equity is about 8.6%.
- Debt to equity is about 0.72x.
- [TRIGGER] pre_earnings_window: pre_earnings_window (pre_earnings_window) on PFE — reason=Pre-earnings freshness window T-1 for PFE Q2 2026 (confirmed via fmp); urgency=high; watcher=pre_earnings_window; days_out=1; source_id=fmp:PFE:2026-08-04; date_basis=fmp_earnings_calendar; date_source=fmp; offset_days=1; report_date=2026-08-04; period_label=Q2 2026; window_label=T-1; eps_estimated=0.68; contributing_watchers=pre_earnings_window (source=fmp; url=pew:Q2 2026:T-1)
- Management signal detected: purchase the targeted number of shares on the date of executing the accelerated share repurchase agreement.
- pfe-20260329 0000078003 12/31 2026 Q1 false one 444 225 xbrli:shares iso4217:USD iso4217:USD xbrli:shares pfe:segment pfe:payment xbrli:pure pfe:case pfe:patent pfe:complaint 0000078003 2026-01-01 2026-03-29 0000078003 us-gaap:CommonStockMember 2026-01-01 2026-03-29 0000078003 pfe:NotesDue20271.000Member 2026-01-01 2026-03-29 0000078003 pfe:NotesDue20292.875Member 2026-01-01 2026-03-29 0000078003 pfe:NotesDue20323.250Member 2026-01-01 2026-03-29 0000078003 pfe:NotesDue20373.875Member 2026-01-01 2026-03-29 0000078003 pfe:NotesDue20454.250Member 2026-01-01 2026-03-29 0000078003 2026-04-29 0000078003 us-gaap:ProductMember 2026-01-01 2026-03-29 0000078003 us-gaap:ProductMember 2025-01-01 2025-03-30 0000078003 2025-01-01 2025-03-30 0000078003 us-gaap:RoyaltyMember 2026-01-01 2026-03-29 0000078003 us-gaap:RoyaltyMember 2025-01-01 2025-03-30 0000078003 2026-03-29 0000078003 2025-12-31 0000078003 us-gaap:CommonStockMember 2025-12-31 0000078003 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0000078003 us-gaap:TreasuryStockCommonMember 2025-12-31 0000078003 us-gaap:RetainedEarningsMember 2025-12-31 0000078003 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-12-31 0000078003 us-gaap:ParentMember 2025-12-31 0000078003 us-gaap:NoncontrollingInterestMember 2025-12-31 0000078003 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-29 0000078003 us-gaap:ParentMember 2026-01-01 2026-03-29 0000078003 us-gaap:NoncontrollingInterestMember 2026-01-01 2026-03-29 0000078003 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-01-01 2026-03-29 0000078003 us-gaap:CommonStockMember 2026-01-01 2026-03-29 0000078003 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-29 0000078003 us-gaap:TreasuryStockCommonMember 2026-01-01 2026-03-29 0000078003 us-gaap:CommonStockMember 2026-03-29 0000078003 us-gaap:AdditionalPaidInCapitalMember 2026-03-29 0000078003 us-gaap:TreasuryStockCommonMember 2026-03-29 0000078003 us-gaap:RetainedEarningsMember 2026-03-29 0000078003 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-03-29 0000078003 us-gaap:ParentMember 2026-03-29 0000078003 us-gaap:NoncontrollingInterestMember 2026-03-29 0000078003 us-gaap:CommonStockMember 2024-12-31 0000078003 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000078003 us-gaap:TreasuryStockCommonMember 2024-12-31 0000078003 us-gaap:RetainedEarningsMember 2024-12-31 0000078003 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0000078003 us-gaap:ParentMember 2024-12-31 0000078003 us-gaap:NoncontrollingInterestMember 2024-12-31 0000078003 2024-12-31 0000078003 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-30 0000078003 us-gaap:ParentMember 2025-01-01 2025-03-30 0000078003 us-gaap:NoncontrollingInterestMember 2025-01-01 2025-03-30 0000078003 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-30 0000078003 us-gaap:CommonStockMember 2025-01-01 2025-03-30 0000078003 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-30 0000078003 us-gaap:TreasuryStockCommonMember 2025-01-01 2025-03-30 0000078003 us-gaap:CommonStockMember 2025-03-30 0000078003 us-gaap:AdditionalPaidInCapitalMember 2025-03-30 0000078003 us-gaap:TreasuryStockCommonMember 2025-03-30 0000078003 us-gaap:RetainedEarningsMember 2025-03-30 0000078003 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-30 0000078003 us-gaap:ParentMember 2025-03-30 0000078003 us-gaap:NoncontrollingInterestMember 2025-03-30 0000078003 2025-03-30 0000078003 us-gaap:AccountsReceivableMember 2026-03-29 0000078003 us-gaap:AccountsReceivableMember 2025-12-31 0000078003 us-gaap:OtherCurrentLiabilitiesMember 2026-03-29 0000078003 us-gaap:OtherCurrentLiabilitiesMember 2025-12-31 0000078003 us-gaap:OtherNoncurrentLiabilitiesMember 2026-03-29 0000078003 us-gaap:OtherNoncurrentLiabilitiesMember 2025-12-31 0000078003 pfe:MetseraMember 2025-11-13 0000078003 pfe:TotalPaymentsToFormerMetseraShareholdersMember pfe:MetseraMember 2025-11-13 0000078003 pfe:Phase3ClinicalTrialMember pfe:MetseraMember 2025-11-13 0000078003 pfe:FDAApprovalOfMET097iMember pfe:MetseraMember 2025-11-13 0000078003 pfe:FDAApprovalOfMET097iMET233iMember pfe:MetseraMember 2025-11-13 0000078003 pfe:MetseraMember 2025-11-13 2025-11-13 0000078003 pfe:SciwindBiosciencesMember pfe:InLicensingAgreementMember 2026-02-01 2026-02-28 0000078003 pfe:ViivHealthcareLimitedMember us-gaap:SubsequentEventMember 2026-03-30 0000078003 pfe:ViivHealthcareLimitedMember us-gaap:SubsequentEventMember 2026-03-31 0000078003 pfe:ViivHealthcareLimitedMember us-gaap:SubsequentEventMember 2026-03-31 2026-03-31 0000078003 pfe:RealigningOurCostBaseProgramInitialPhaseMember 2026-03-29 0000078003 pfe:BiopharmaSegmentMember pfe:RealigningOurCostBaseProgramInitialPhaseMember 2026-03-29 0000078003 us-gaap:OtherRestructuringMember pfe:BiopharmaSegmentMember pfe:RealigningOurCostBaseProgramResearchAndDevelopmentMember 2026-03-29 0000078003 pfe:RealigningOurCostBaseProgramMember 2026-03-29 0000078003 pfe:BiopharmaSegmentMember pfe:RealigningOurCostBaseProgramMember 2026-03-29 0000078003 pfe:BiopharmaSegmentMember pfe:RealigningOurCostBaseProgramMember 2023-10-02 2026-03-29 0000078003 pfe:BiopharmaSegmentMember pfe:ManufacturingOptimizationProgramPhaseOneMember 2026-03-29 0000078003 pfe:BiopharmaSegmentMember pfe:ManufacturingOptimizationProgramMember 2026-03-29 0000078003 pfe:BiopharmaSegmentMember pfe:ManufacturingOptimizationProgramMember 2024-04-01 2026-03-29 0000078003 us-gaap:OtherNonoperatingIncomeExpenseMember 2026-01-01 2026-03-29 0000078003 us-gaap:OtherNonoperatingIncomeExpenseMember 2025-01-01 2025-03-30 0000078003 us-gaap:CostOfSalesMember 2026-01-01 2026-03-29 0000078003 us-gaap:CostOfSalesMember 2025-01-01 2025-03-30 0000078003 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2026-01-01 2026-03-29 0000078003 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2025-01-01 2025-03-30 0000078003 us-gaap:ResearchAndDevelopmentExpenseMember 2026-01-01 2026-03-29 0000078003 us-gaap:ResearchAndDevelopmentExpenseMember 2025-01-01 2025-03-30 0000078003 pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:BiopharmaSegmentMember pfe:RealigningOurCostBaseProgramMember 2026-01-01 2026-03-29 0000078003 pfe:BiopharmaSegmentMember pfe:ManufacturingOptimizationProgramMember 2026-01-01 2026-03-29 0000078003 pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:BiopharmaSegmentMember pfe:RealigningOurCostBaseProgramMember 2025-01-01 2025-03-30 0000078003 pfe:BiopharmaSegmentMember pfe:ManufacturingOptimizationProgramMember 2025-01-01 2025-03-30 0000078003 us-gaap:EmployeeSeveranceMember 2025-12-31 0000078003 pfe:AssetImpairmentsMember 2025-12-31 0000078003 us-gaap:OtherRestructuringMember 2025-12-31 0000078003 us-gaap:EmployeeSeveranceMember 2026-01-01 2026-03-29 0000078003 pfe:AssetImpairmentsMember 2026-01-01 2026-03-29 0000078003 us-gaap:OtherRestructuringMember 2026-01-01 2026-03-29 0000078003 us-gaap:EmployeeSeveranceMember 2026-03-29 0000078003 pfe:AssetImpairmentsMember 2026-03-29 0000078003 us-gaap:OtherRestructuringMember 2026-03-29 0000078003 us-gaap:InProcessResearchAndDevelopmentMember 2025-01-01 2025-03-30 0000078003 us-gaap:AccumulatedTranslationAdjustmentMember 2025-12-31 0000078003 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2025-12-31 0000078003 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2025-12-31 0000078003 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember 2025-12-31 0000078003 us-gaap:AccumulatedTranslationAdjustmentMember 2026-01-01 2026-03-29 0000078003 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2026-01-01 2026-03-29 0000078003 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2026-01-01 2026-03-29 0000078003 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember 2026-01-01 2026-03-29 0000078003 us-gaap:AccumulatedTranslationAdjustmentMember 2026-03-29 0000078003 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2026-03-29 0000078003 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2026-03-29 0000078003 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember 2026-03-29 0000078003 us-gaap:ShortTermInvestmentsMember 2026-03-29 0000078003 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel1Member 2026-03-29 0000078003 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member 2026-03-29 0000078003 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel3Member 2026-03-29 0000078003 us-gaap:ShortTermInvestmentsMember 2025-12-31 0000078003 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel1Member 2025-12-31 0000078003 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member 2025-12-31 0000078003 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel3Member 2025-12-31 0000078003 us-gaap:ForeignGovernmentDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember 2026-03-29 0000078003 us-gaap:ForeignGovernmentDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel1Member 2026-03-29 0000078003 us-gaap:ForeignGovernmentDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member 2026-03-29 0000078003 us-gaap:ForeignGovernmentDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel3Member 2026-03-29 0000078003 us-gaap:ForeignGovernmentDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember 2025-12-31 0000078003 us-gaap:ForeignGovernmentDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel1Member 2025-12-31 0000078003 us-gaap:ForeignGovernmentDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member 2025-12-31 0000078003 us-gaap:ForeignGovernmentDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel3Member 2025-12-31 0000078003 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember 2026-03-29 0000078003 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel1Member 2026-03-29 0000078003 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member 2026-03-29 0000078003 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel3Member 2026-03-29 0000078003 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember 2025-12-31 0000078003 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel1Member 2025-12-31 0000078003 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member 2025-12-31 0000078003 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel3Member 2025-12-31 0000078003 us-gaap:CorporateDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember 2026-03-29 0000078003 us-gaap:CorporateDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel1Member 2026-03-29 0000078003 us-gaap:CorporateDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member 2026-03-29 0000078003 us-gaap:CorporateDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel3Member 2026-03-29 0000078003 us-gaap:CorporateDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember 2025-12-31 0000078003 us-gaap:CorporateDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel1Member 2025-12-31 0000078003 us-gaap:CorporateDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member 2025-12-31 0000078003 us-gaap:CorporateDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel3Member 2025-12-31 0000078003 us-gaap:InterestRateContractMember 2026-03-29 0000078003 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel1Member 2026-03-29 0000078003 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member 2026-03-29 0000078003 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel3Member 2026-03-29 0000078003 us-gaap:InterestRateContractMember 2025-12-31 0000078003 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel1Member 2025-12-31 0000078003 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member 2025-12-31 0000078003 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel3Member 2025-12-31 0000078003 us-gaap:ForeignExchangeContractMember 2026-03-29 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member 2026-03-29 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member 2026-03-29 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member 2026-03-29 0000078003 us-gaap:ForeignExchangeContractMember 2025-12-31 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member 2025-12-31 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member 2025-12-31 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member 2025-12-31 0000078003 us-gaap:FairValueInputsLevel1Member 2026-03-29 0000078003 us-gaap:FairValueInputsLevel2Member 2026-03-29 0000078003 us-gaap:FairValueInputsLevel3Member 2026-03-29 0000078003 us-gaap:FairValueInputsLevel1Member 2025-12-31 0000078003 us-gaap:FairValueInputsLevel2Member 2025-12-31 0000078003 us-gaap:FairValueInputsLevel3Member 2025-12-31 0000078003 pfe:LongtermInvestmentsMember 2026-03-29 0000078003 pfe:LongtermInvestmentsMember us-gaap:FairValueInputsLevel1Member 2026-03-29 0000078003 pfe:LongtermInvestmentsMember us-gaap:FairValueInputsLevel2Member 2026-03-29 0000078003 pfe:LongtermInvestmentsMember us-gaap:FairValueInputsLevel3Member 2026-03-29 0000078003 pfe:LongtermInvestmentsMember 2025-12-31 0000078003 pfe:LongtermInvestmentsMember us-gaap:FairValueInputsLevel1Member 2025-12-31 0000078003 pfe:LongtermInvestmentsMember us-gaap:FairValueInputsLevel2Member 2025-12-31 0000078003 pfe:LongtermInvestmentsMember us-gaap:FairValueInputsLevel3Member 2025-12-31 0000078003 us-gaap:ForeignGovernmentDebtSecuritiesMember pfe:LongtermInvestmentsMember 2026-03-29 0000078003 us-gaap:ForeignGovernmentDebtSecuritiesMember pfe:LongtermInvestmentsMember us-gaap:FairValueInputsLevel1Member 2026-03-29 0000078003 us-gaap:ForeignGovernmentDebtSecuritiesMember pfe:LongtermInvestmentsMember us-gaap:FairValueInputsLevel2Member 2026-03-29 0000078003 us-gaap:ForeignGovernmentDebtSecuritiesMember pfe:LongtermInvestmentsMember us-gaap:FairValueInputsLevel3Member 2026-03-29 0000078003 us-gaap:ForeignGovernmentDebtSecuritiesMember pfe:LongtermInvestmentsMember 2025-12-31 0000078003 us-gaap:ForeignGovernmentDebtSecuritiesMember pfe:LongtermInvestmentsMember us-gaap:FairValueInputsLevel1Member 2025-12-31 0000078003 us-gaap:ForeignGovernmentDebtSecuritiesMember pfe:LongtermInvestmentsMember us-gaap:FairValueInputsLevel2Member 2025-12-31 0000078003 us-gaap:ForeignGovernmentDebtSecuritiesMember pfe:LongtermInvestmentsMember us-gaap:FairValueInputsLevel3Member 2025-12-31 0000078003 us-gaap:CorporateDebtSecuritiesMember pfe:LongtermInvestmentsMember 2026-03-29 0000078003 us-gaap:CorporateDebtSecuritiesMember pfe:LongtermInvestmentsMember us-gaap:FairValueInputsLevel1Member 2026-03-29 0000078003 us-gaap:CorporateDebtSecuritiesMember pfe:LongtermInvestmentsMember us-gaap:FairValueInputsLevel2Member 2026-03-29 0000078003 us-gaap:CorporateDebtSecuritiesMember pfe:LongtermInvestmentsMember us-gaap:FairValueInputsLevel3Member 2026-03-29 0000078003 us-gaap:CorporateDebtSecuritiesMember pfe:LongtermInvestmentsMember 2025-12-31 0000078003 us-gaap:CorporateDebtSecuritiesMember pfe:LongtermInvestmentsMember us-gaap:FairValueInputsLevel1Member 2025-12-31 0000078003 us-gaap:CorporateDebtSecuritiesMember pfe:LongtermInvestmentsMember us-gaap:FairValueInputsLevel2Member 2025-12-31 0000078003 us-gaap:CorporateDebtSecuritiesMember pfe:LongtermInvestmentsMember us-gaap:FairValueInputsLevel3Member 2025-12-31 0000078003 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2026-03-29 0000078003 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-12-31 0000078003 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueInputsLevel2Member 2026-03-29 0000078003 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueInputsLevel2Member 2025-12-31 0000078003 us-gaap:ForeignGovernmentDebtSecuritiesMember 2026-03-29 0000078003 us-gaap:ForeignGovernmentDebtSecuritiesMember 2025-12-31 0000078003 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2026-03-29 0000078003 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2025-12-31 0000078003 us-gaap:CorporateDebtSecuritiesMember 2026-03-29 0000078003 us-gaap:CorporateDebtSecuritiesMember 2025-12-31 0000078003 pfe:CorporateTimeDepositsAndOtherMember 2026-03-29 0000078003 pfe:CorporateTimeDepositsAndOtherMember 2025-12-31 0000078003 us-gaap:UnsecuredDebtMember 2026-03-29 0000078003 us-gaap:UnsecuredDebtMember 2025-12-31 0000078003 us-gaap:ForeignExchangeContractMember 2026-01-01 2026-03-29 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2026-03-29 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2025-12-31 0000078003 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2026-03-29 0000078003 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2025-12-31 0000078003 us-gaap:DesignatedAsHedgingInstrumentMember 2026-03-29 0000078003 us-gaap:DesignatedAsHedgingInstrumentMember 2025-12-31 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2026-03-29 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2025-12-31 0000078003 us-gaap:SalesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2026-03-29 0000078003 us-gaap:SalesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2025-12-31 0000078003 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2026-01-01 2026-03-29 0000078003 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2025-01-01 2025-03-30 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2026-01-01 2026-03-29 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2025-01-01 2025-03-30 0000078003 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:FairValueHedgingMember 2026-01-01 2026-03-29 0000078003 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:FairValueHedgingMember 2025-01-01 2025-03-30 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:NetInvestmentHedgingMember 2026-01-01 2026-03-29 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:NetInvestmentHedgingMember 2025-01-01 2025-03-30 0000078003 pfe:ForeignCurrencyShortTermBorrowingsMember us-gaap:DesignatedAsHedgingInstrumentMember 2026-01-01 2026-03-29 0000078003 pfe:ForeignCurrencyShortTermBorrowingsMember us-gaap:DesignatedAsHedgingInstrumentMember 2025-01-01 2025-03-30 0000078003 pfe:ForeignCurrencyDebtMember us-gaap:DesignatedAsHedgingInstrumentMember 2026-01-01 2026-03-29 0000078003 pfe:ForeignCurrencyDebtMember us-gaap:DesignatedAsHedgingInstrumentMember 2025-01-01 2025-03-30 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2026-01-01 2026-03-29 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2025-01-01 2025-03-30 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2026-01-01 2026-03-29 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2025-01-01 2025-03-30 0000078003 pfe:ForeignCurrencyDebtMember 2026-03-29 0000078003 pfe:ForeignCurrencyDebtMember 2025-12-31 0000078003 us-gaap:DevelopedTechnologyRightsMember 2026-03-29 0000078003 us-gaap:DevelopedTechnologyRightsMember 2025-12-31 0000078003 us-gaap:TradeNamesMember 2026-03-29 0000078003 us-gaap:TradeNamesMember 2025-12-31 0000078003 pfe:LicensingAgreementsAndOtherMember 2026-03-29 0000078003 pfe:LicensingAgreementsAndOtherMember 2025-12-31 0000078003 us-gaap:InProcessResearchAndDevelopmentMember 2026-03-29 0000078003 us-gaap:InProcessResearchAndDevelopmentMember 2025-12-31 0000078003 pfe:LicensingAgreementsAndOtherMember 2026-03-29 0000078003 pfe:LicensingAgreementsAndOtherMember 2025-12-31 0000078003 pfe:TukysaMember us-gaap:InProcessResearchAndDevelopmentMember 2026-01-01 2026-03-29 0000078003 pfe:TukysaMember us-gaap:DevelopedTechnologyRightsMember 2026-01-01 2026-03-29 0000078003 country:US us-gaap:PensionPlansDefinedBenefitMember 2026-01-01 2026-03-29 0000078003 country:US us-gaap:PensionPlansDefinedBenefitMember 2025-01-01 2025-03-30 0000078003 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2026-01-01 2026-03-29 0000078003 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2025-01-01 2025-03-30 0000078003 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2026-01-01 2026-03-29 0000078003 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2025-01-01 2025-03-30 0000078003 pfe:VyndaqelLitigationCaseMember us-gaap:SubsequentEventMember 2026-04-01 2026-04-30 0000078003 pfe:MicroLabsChangzhouAndBioconPatentInfringementCaseMember 2026-03-01 2026-03-29 0000078003 pfe:ComirnatyMember pfe:ModernaTXUSPatentInfringementCaseMember 2022-08-01 2022-08-31 0000078003 pfe:ComirnatyMember pfe:ModernaTXUSPatentInfringementCaseMember 2024-03-01 2024-03-31 0000078003 pfe:ComirnatyMember pfe:ModernaTXUSPatentInfringementCaseMember 2025-03-01 2025-03-30 0000078003 pfe:ComirnatyMember pfe:ModernaTXEuropeanPatentInfringementCaseMember 2022-08-01 2022-08-31 0000078003 pfe:ComirnatyMember pfe:ModernaTXEuropeanPatentInfringementCaseMember 2022-09-01 2022-09-30 0000078003 pfe:ComirnatyMember pfe:ModernaTXEuropeanPatentInfringementCaseMember 2023-11-01 2023-11-30 0000078003 pfe:ComirnatyMember pfe:ModernaTXEuropeanPatentInfringementCaseMember 2024-07-01 2024-07-31 0000078003 pfe:ComirnatyMember pfe:ArbutusAndGenevantUSPatentInfringementCaseMember 2023-04-01 2023-04-30 0000078003 pfe:ComirnatyMember pfe:GlaxoSmithKlineBiologicsSAAndGlaxoSmithKlineLLCUSPatentInfringementCaseMember 2024-04-01 2024-04-30 0000078003 pfe:ComirnatyMember pfe:GlaxoSmithKlineBiologicsSAAndGlaxoSmithKlineLLCUSPatentInfringementCaseMember 2024-08-01 2024-08-31 0000078003 pfe:ComirnatyMember pfe:GlaxoSmithKlineBiologicsSAAndGlaxoSmithKlineLLCIrelandPatentInfringementCaseMember 2025-07-01 2025-07-31 0000078003 pfe:ComirnatyMember pfe:GlaxoSmithKlineBiologicsSAAndGlaxoSmithKlineLLCUnifiedPatentCourtPatentInfringementCaseMember 2025-07-01 2025-07-31 0000078003 us-gaap:PendingLitigationMember pfe:GreenstoneAntitrustLitigationMember 2020-12-31 0000078003 us-gaap:OperatingSegmentsMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 us-gaap:OperatingSegmentsMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 us-gaap:CorporateNonSegmentMember 2026-01-01 2026-03-29 0000078003 us-gaap:CorporateNonSegmentMember 2025-01-01 2025-03-30 0000078003 us-gaap:MaterialReconcilingItemsMember pfe:ReconcilingItemsAmortizationOfIntangibleAssetsMember 2026-01-01 2026-03-29 0000078003 us-gaap:MaterialReconcilingItemsMember pfe:ReconcilingItemsAmortizationOfIntangibleAssetsMember 2025-01-01 2025-03-30 0000078003 us-gaap:MaterialReconcilingItemsMember pfe:ReconcilingItemsAcquisitionRelatedCostsMember 2026-01-01 2026-03-29 0000078003 us-gaap:MaterialReconcilingItemsMember pfe:ReconcilingItemsAcquisitionRelatedCostsMember 2025-01-01 2025-03-30 0000078003 us-gaap:MaterialReconcilingItemsMember pfe:ReconcilingItemsOtherMember 2026-01-01 2026-03-29 0000078003 us-gaap:MaterialReconcilingItemsMember pfe:ReconcilingItemsOtherMember 2025-01-01 2025-03-30 0000078003 us-gaap:CorporateNonSegmentMember us-gaap:ReclassificationOtherMember 2025-01-01 2025-03-30 0000078003 pfe:ViivHealthcareLimitedMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:ViivHealthcareLimitedMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 country:US 2026-01-01 2026-03-29 0000078003 country:US 2025-01-01 2025-03-30 0000078003 pfe:InternationalDevelopedMarketsMember 2026-01-01 2026-03-29 0000078003 pfe:InternationalDevelopedMarketsMember 2025-01-01 2025-03-30 0000078003 pfe:InternationalEmergingMarketsMember 2026-01-01 2026-03-29 0000078003 pfe:InternationalEmergingMarketsMember 2025-01-01 2025-03-30 0000078003 pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:EliquisMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:EliquisMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:PrevnarPrevenarFamilyMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:PrevnarPrevenarFamilyMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:NurtecODTVyduraMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:NurtecODTVyduraMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:ComirnatyMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:ComirnatyMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:PaxlovidEUALabeledMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:PaxlovidEUALabeledMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:AbrysvoMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:AbrysvoMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:FSMEIMMUNTicoVacMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:FSMEIMMUNTicoVacMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:OtherPrimaryCareProductsMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:OtherPrimaryCareProductsMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:OncologyMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:OncologyMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:IbranceMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:IbranceMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:PadcevMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:PadcevMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:XtandiMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:XtandiMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:LorbrenaMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:LorbrenaMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:InlytaMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:InlytaMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:AdcetrisMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:AdcetrisMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:BraftoviMektoviMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:BraftoviMektoviMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:BosulifMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:BosulifMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:TukysaMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:TukysaMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:OrgovyxMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:OrgovyxMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:ElrexfioMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:ElrexfioMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:TalzennaMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:TalzennaMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:TivdakMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:TivdakMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:OtherOncologyProductsMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:OtherOncologyProductsMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:VyndaqelMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:VyndaqelMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:XeljanzMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:XeljanzMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:ZaviceftaMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:ZaviceftaMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:EnbrelMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:EnbrelMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:OctagamMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:OctagamMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:GenotropinMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:GenotropinMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:CibinqoMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:CibinqoMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:OtherSpecialtyCareMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:OtherSpecialtyCareMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:HospitalAndBiosimilarsMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:HospitalAndBiosimilarsMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:OncologyBiosimilarsMember pfe:HospitalAndBiosimilarsMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:OncologyBiosimilarsMember pfe:HospitalAndBiosimilarsMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:SulperazonMember pfe:HospitalAndBiosimilarsMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:SulperazonMember pfe:HospitalAndBiosimilarsMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:InflectraMember pfe:HospitalAndBiosimilarsMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:InflectraMember pfe:HospitalAndBiosimilarsMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:ZithromaxZmaxMember pfe:HospitalAndBiosimilarsMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:ZithromaxZmaxMember pfe:HospitalAndBiosimilarsMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:AllOtherHospitalAndBiosimilarsMember pfe:HospitalAndBiosimilarsMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:AllOtherHospitalAndBiosimilarsMember pfe:HospitalAndBiosimilarsMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:PfizerCentreOneMember 2026-01-01 2026-03-29 0000078003 pfe:PfizerCentreOneMember 2025-01-01 2025-03-30 0000078003 pfe:BiopharmaSegmentMember pfe:U.S.CommercialDivisionMember 2026-01-01 2026-03-29 0000078003 pfe:BiopharmaSegmentMember pfe:U.S.CommercialDivisionMember 2025-01-01 2025-03-30 0000078003 pfe:BiopharmaSegmentMember pfe:InternationalCommercialDivisionMember 2026-01-01 2026-03-29 0000078003 pfe:BiopharmaSegmentMember pfe:InternationalCommercialDivisionMember 2025-01-01 2025-03-30 0000078003 pfe:BiopharmaSegmentMember pfe:GlobalHospitalAndBiosimilarsDivisionMember 2026-01-01 2026-03-29 0000078003 pfe:BiopharmaSegmentMember pfe:GlobalHospitalAndBiosimilarsDivisionMember 2025-01-01 2025-03-30 0000078003 pfe:TotalAllianceBiopharmaceuticalsMember 2026-01-01 2026-03-29 0000078003 pfe:TotalAllianceBiopharmaceuticalsMember 2025-01-01 2025-03-30 0000078003 pfe:ComirnatyMember 2026-03-29 0000078003 pfe:PaxlovidMember 2026-03-29 0000078003 pfe:PaxlovidAndComirnatyMember pfe:GovernmentAndGovernmentSponsoredMember 2026-03-29 0000078003 pfe:PaxlovidAndComirnatyMember pfe:GovernmentAndGovernmentSponsoredMember 2025-12-31 0000078003 pfe:PaxlovidAndComirnatyMember pfe:GovernmentAndGovernmentSponsoredMember 2026-01-01 2026-03-29 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C.
Bull / Bear case
Generated · model-assistedBULL CASE · 4
Pfizer's net income surged with a 94.7% two-year CAGR from FY2023 to FY2025, demonstrating strong profitability growth.
Analysts project 16.3% upside to a mean price target of $28.97, suggesting undervaluation relative to current market price.
Free cash flow grew 8.4% year-over-year to $9.8 billion in FY2025, indicating robust cash generation capabilities.
Cash conversion ratio of 0.97 exceeds the pharmaceutical cohort median of 0.95, reflecting efficient earnings quality.
BEAR CASE · 5
Pfizer faces high liquidity risk and medium dilution risk, posing significant threats to shareholder value and financial stability.
The debt-to-equity ratio of 0.72 places Pfizer in the bottom quartile compared to 877 pharmaceutical peers.
Return on equity of 2.98% barely exceeds the cohort median of 2.92%, indicating limited capital efficiency gains.
Revenue growth slowed to just 1.7% year-over-year in FY2025, signaling potential stagnation in top-line expansion.
Negative book value of -$11.9 billion suggests accumulated losses or aggressive accounting treatments impacting balance sheet health.
In focus — financials by report
Quarterly
Annual
QUARTERLYFiled 2026-03-29
Q4 2025 · Quarter highlights
Revenue $14.45B; Net margin 18.6%.
Revenue$14.45B
Operating income—
Net income$2.69B
Free cash flow$2.18B
EPS—
Operating cash flow$2.62B
Financials
Income statement
Revenue$14.45B
Gross profit—
Operating income—
Net income$2.69B
Margins
Gross margin—
Operating margin—
Net margin18.6%
FCF margin15.1%
Balance sheet
Total assets$207.62B
Total liabilities$117.21B
Total equity$90.10B
Cash & equivalents$1.70B
Long-term debt$60.56B
Cash flow
Operating cash flow$2.62B
CapEx$436.0M
Free cash flow$2.18B
SBC$272.0M
Highlights
- ▍Revenue $14.45B
- ▍Net margin 18.6%
QUARTERLYFiled 2025-09-28
Q2 2025 · Quarter highlights
Revenue $45.02B; Net margin 20.9%.
Revenue$45.02B
Operating income—
Net income$9.42B
Free cash flow$4.57B
EPS—
Operating cash flow$6.36B
Financials
Income statement
Revenue$45.02B
Gross profit—
Operating income—
Net income$9.42B
Margins
Gross margin—
Operating margin—
Net margin20.9%
FCF margin10.2%
Balance sheet
Total assets$208.73B
Total liabilities$115.64B
Total equity$92.80B
Cash & equivalents$1.34B
Long-term debt$57.41B
Cash flow
Operating cash flow$6.36B
CapEx$1.78B
Free cash flow$4.57B
SBC$574.0M
Highlights
- ▍Revenue $45.02B
- ▍Net margin 20.9%
QUARTERLYFiled 2025-06-29
Q1 2025 · Quarter highlights
Revenue $28.37B; Net margin 20.7%.
Revenue$28.37B
Operating income—
Net income$5.88B
Free cash flow$571.0M
EPS—
Operating cash flow$1.75B
Financials
Income statement
Revenue$28.37B
Gross profit—
Operating income—
Net income$5.88B
Margins
Gross margin—
Operating margin—
Net margin20.7%
FCF margin2.0%
Balance sheet
Total assets$206.09B
Total liabilities$117.08B
Total equity$88.69B
Cash & equivalents$1.64B
Long-term debt$57.50B
Cash flow
Operating cash flow$1.75B
CapEx$1.18B
Free cash flow$571.0M
SBC$373.0M
Highlights
- ▍Revenue $28.37B
- ▍Net margin 20.7%
ANNUALFiled 2025-12-31
FY 2025 · Full-year highlights
Revenue $62.58B; Net margin 12.4%.
Revenue$62.58B
Operating income—
Net income$7.77B
Free cash flow$9.07B
EPS—
Operating cash flow$11.70B
Financials
Income statement
Revenue$62.58B
Gross profit—
Operating income—
Net income$7.77B
Margins
Gross margin—
Operating margin—
Net margin12.4%
FCF margin14.5%
Balance sheet
Total assets$208.16B
Total liabilities$121.39B
Total equity$86.48B
Cash & equivalents$1.14B
Long-term debt$61.64B
Cash flow
Operating cash flow$11.70B
CapEx$2.63B
Free cash flow$9.07B
SBC$799.0M
P&L flow · revenue → net income
Highlights
- ▍Revenue $62.58B
- ▍Net margin 12.4%
ANNUALFiled 2024-12-31
FY 2024 · Full-year highlights
Revenue $63.63B; Net margin 12.6%.
Revenue$63.63B
Operating income—
Net income$8.03B
Free cash flow$9.84B
EPS—
Operating cash flow$12.74B
Financials
Income statement
Revenue$63.63B
Gross profit—
Operating income—
Net income$8.03B
Margins
Gross margin—
Operating margin—
Net margin12.6%
FCF margin15.5%
Balance sheet
Total assets$213.40B
Total liabilities$124.90B
Total equity$88.20B
Cash & equivalents$1.04B
Long-term debt$57.41B
Cash flow
Operating cash flow$12.74B
CapEx$2.91B
Free cash flow$9.84B
SBC$877.0M
Highlights
- ▍Revenue $63.63B
- ▍Net margin 12.6%
ANNUALFiled 2024-12-31
FY 2025 · Full-year highlights
Revenue $63.63B; Net margin 12.6%.
Revenue$63.63B
Operating income—
Net income$8.03B
Free cash flow$9.84B
EPS—
Operating cash flow$12.74B
Financials
Income statement
Revenue$63.63B
Gross profit—
Operating income—
Net income$8.03B
Margins
Gross margin—
Operating margin—
Net margin12.6%
FCF margin15.5%
Balance sheet
Total assets$213.40B
Total liabilities$124.90B
Total equity$88.20B
Cash & equivalents$1.04B
Long-term debt$57.41B
Cash flow
Operating cash flow$12.74B
CapEx$2.91B
Free cash flow$9.84B
SBC$877.0M
Highlights
- ▍Revenue $63.63B
- ▍Net margin 12.6%
ANNUALFiled 2023-12-31
FY 2023 · Full-year highlights
Revenue $50.91B; Net margin 4.2%.
Revenue$50.91B
Operating income—
Net income$2.12B
Free cash flow$4.79B
EPS—
Operating cash flow$8.70B
Financials
Income statement
Revenue$50.91B
Gross profit—
Operating income—
Net income$2.12B
Margins
Gross margin—
Operating margin—
Net margin4.2%
FCF margin9.4%
Balance sheet
Total assets$226.50B
Total liabilities$137.21B
Total equity$89.01B
Cash & equivalents$2.85B
Long-term debt$61.54B
Cash flow
Operating cash flow$8.70B
CapEx$3.91B
Free cash flow$4.79B
SBC$525.0M
Highlights
- ▍Revenue $50.91B
- ▍Net margin 4.2%
ANNUALFiled 2023-12-31
FY 2024 · Full-year highlights
Revenue $59.55B; Net margin 3.6%.
Revenue$59.55B
Operating income—
Net income$2.12B
Free cash flow$4.79B
EPS—
Operating cash flow$8.70B
Financials
Income statement
Revenue$59.55B
Gross profit—
Operating income—
Net income$2.12B
Margins
Gross margin—
Operating margin—
Net margin3.6%
FCF margin8.0%
Balance sheet
Total assets$226.50B
Total liabilities$137.21B
Total equity$89.01B
Cash & equivalents$2.85B
Long-term debt$61.54B
Cash flow
Operating cash flow$8.70B
CapEx$3.91B
Free cash flow$4.79B
SBC$525.0M
Highlights
- ▍Revenue $59.55B
- ▍Net margin 3.6%
Valuation FY
Market price
$25,05
Market cap
$141.61B
Enterprise valueⓘ
$204.34B
P/Eⓘ
18.2x
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
3.3x
EV / Op incomeⓘ
—
EV / OCFⓘ
17.5x
P / Bⓘ
—
P / Tangible bookⓘ
—
Tangible book
-$11.92B
Net cashⓘ
-$62.72B
Current ratioⓘ
1.2
Debt / equityⓘ
0.7
ROAⓘ
3.7%
ROEⓘ
8.6%
Cash conversionⓘ
151.0%
CapEx / revenueⓘ
4.2%
SBC / revenueⓘ
1.3%
Dilution ratioⓘ
—
Revenue by segment
Biologics—
low · business_description · 2026-07-03
Branded / Innovative Medicines—
low · business_description · 2026-07-03
Vaccines—
low · business_description · 2026-07-03
Business relationships
Business relationships263 disclosed relationships · 1 type · extracted from filings & disclosures
Subsidiaries263
EX21:00b917d9f1edEX21:00b917d9f1edSubsidiarie97%
EX21:01132347bb38EX21:01132347bb38Subsidiarie97%
EX21:02196e78de36EX21:02196e78de36Subsidiarie97%
EX21:02a4586a019fEX21:02a4586a019fSubsidiarie97%
EX21:031dcbad376cEX21:031dcbad376cSubsidiarie97%
EX21:033057ad7a8aEX21:033057ad7a8aSubsidiarie97%
EX21:058ff4192a36EX21:058ff4192a36Subsidiarie97%
EX21:05c97aad09c7EX21:05c97aad09c7Subsidiarie97%
EX21:0637e158fed8EX21:0637e158fed8Subsidiarie97%
EX21:06520b6624dfEX21:06520b6624dfSubsidiarie97%
EX21:079a40dd0cedEX21:079a40dd0cedSubsidiarie97%
EX21:0a9911203cd4EX21:0a9911203cd4Subsidiarie97%
EX21:0adefa213459EX21:0adefa213459Subsidiarie97%
EX21:0bf8367abf1dEX21:0bf8367abf1dSubsidiarie97%
EX21:0dd5de530884EX21:0dd5de530884Subsidiarie97%
EX21:0e018a632fefEX21:0e018a632fefSubsidiarie97%
EX21:0f069e885153EX21:0f069e885153Subsidiarie97%
EX21:0f27d53a9e09EX21:0f27d53a9e09Subsidiarie97%
EX21:0f29275c6512EX21:0f29275c6512Subsidiarie97%
EX21:0f93ef6e381bEX21:0f93ef6e381bSubsidiarie97%
EX21:11e9c0cd6240EX21:11e9c0cd6240Subsidiarie97%
EX21:139a1056fd17EX21:139a1056fd17Subsidiarie97%
EX21:13aa6361e2daEX21:13aa6361e2daSubsidiarie97%
EX21:13b1b2dbf05fEX21:13b1b2dbf05fSubsidiarie97%
EX21:13d5e3cc6a54EX21:13d5e3cc6a54Subsidiarie97%
EX21:149b00b2aa0cEX21:149b00b2aa0cSubsidiarie97%
EX21:15eaa92c38c1EX21:15eaa92c38c1Subsidiarie97%
EX21:1624caa142f4EX21:1624caa142f4Subsidiarie97%
EX21:177f695658e2EX21:177f695658e2Subsidiarie97%
EX21:18b8015279d3EX21:18b8015279d3Subsidiarie97%
EX21:18d0291bd088EX21:18d0291bd088Subsidiarie97%
EX21:1992c7ce8faaEX21:1992c7ce8faaSubsidiarie97%
EX21:1a18aebaff59EX21:1a18aebaff59Subsidiarie97%
EX21:1c9ac8f37808EX21:1c9ac8f37808Subsidiarie97%
EX21:1d8a92035de9EX21:1d8a92035de9Subsidiarie97%
EX21:1f9640bb912fEX21:1f9640bb912fSubsidiarie97%
EX21:1fba832c4485EX21:1fba832c4485Subsidiarie97%
EX21:20c1412d73fdEX21:20c1412d73fdSubsidiarie97%
EX21:212404c4b5f6EX21:212404c4b5f6Subsidiarie97%
EX21:2125b30bcdc5EX21:2125b30bcdc5Subsidiarie97%
EX21:233fa0b93471EX21:233fa0b93471Subsidiarie97%
EX21:25070739a442EX21:25070739a442Subsidiarie97%
EX21:260815cb15bfEX21:260815cb15bfSubsidiarie97%
EX21:2647cbc8dc8dEX21:2647cbc8dc8dSubsidiarie97%
EX21:274512938494EX21:274512938494Subsidiarie97%
EX21:27471e307408EX21:27471e307408Subsidiarie97%
EX21:292fdf99508fEX21:292fdf99508fSubsidiarie97%
EX21:29b3e3004003EX21:29b3e3004003Subsidiarie97%
EX21:2c9b98e80686EX21:2c9b98e80686Subsidiarie97%
EX21:2d9286f889c4EX21:2d9286f889c4Subsidiarie97%
EX21:2e1b861db681EX21:2e1b861db681Subsidiarie97%
EX21:2e2d82d27cfaEX21:2e2d82d27cfaSubsidiarie97%
EX21:312780c44e48EX21:312780c44e48Subsidiarie97%
EX21:324b1dc9b564EX21:324b1dc9b564Subsidiarie97%
EX21:33ddea5c9da8EX21:33ddea5c9da8Subsidiarie97%
EX21:369f34dfdda3EX21:369f34dfdda3Subsidiarie97%
EX21:37d28dfd2531EX21:37d28dfd2531Subsidiarie97%
EX21:3856ba2549cfEX21:3856ba2549cfSubsidiarie97%
EX21:389136392269EX21:389136392269Subsidiarie97%
EX21:394df09746d4EX21:394df09746d4Subsidiarie97%
EX21:39fadf522ea5EX21:39fadf522ea5Subsidiarie97%
EX21:3b835883e3edEX21:3b835883e3edSubsidiarie97%
EX21:3c98610a07eeEX21:3c98610a07eeSubsidiarie97%
EX21:3ecbf26748daEX21:3ecbf26748daSubsidiarie97%
EX21:3f6dcd95572eEX21:3f6dcd95572eSubsidiarie97%
EX21:3fb8fdeb0883EX21:3fb8fdeb0883Subsidiarie97%
EX21:42b035b0fa30EX21:42b035b0fa30Subsidiarie97%
EX21:43203647ac04EX21:43203647ac04Subsidiarie97%
EX21:442855b173eaEX21:442855b173eaSubsidiarie97%
EX21:475c8cf04deeEX21:475c8cf04deeSubsidiarie97%
EX21:4950df803401EX21:4950df803401Subsidiarie97%
EX21:4a470542543dEX21:4a470542543dSubsidiarie97%
EX21:4b4f971710cbEX21:4b4f971710cbSubsidiarie97%
EX21:4b8a6837b0faEX21:4b8a6837b0faSubsidiarie97%
EX21:4bd5f50aefb5EX21:4bd5f50aefb5Subsidiarie97%
EX21:4c666faa2a9aEX21:4c666faa2a9aSubsidiarie97%
EX21:4d1a34852b54EX21:4d1a34852b54Subsidiarie97%
EX21:4d87afd8c24aEX21:4d87afd8c24aSubsidiarie97%
EX21:4fe45f92d9aeEX21:4fe45f92d9aeSubsidiarie97%
EX21:51250c11512dEX21:51250c11512dSubsidiarie97%
EX21:516f16b91bafEX21:516f16b91bafSubsidiarie97%
EX21:51b1b826c38fEX21:51b1b826c38fSubsidiarie97%
EX21:523fe4c1f1c7EX21:523fe4c1f1c7Subsidiarie97%
EX21:52e9b6caa667EX21:52e9b6caa667Subsidiarie97%
EX21:546b88bff49bEX21:546b88bff49bSubsidiarie97%
EX21:56cb556a09b3EX21:56cb556a09b3Subsidiarie97%
EX21:5718bb1fca24EX21:5718bb1fca24Subsidiarie97%
EX21:572e31f55b6aEX21:572e31f55b6aSubsidiarie97%
EX21:577e91f6efcbEX21:577e91f6efcbSubsidiarie97%
EX21:57cbdce8e6eaEX21:57cbdce8e6eaSubsidiarie97%
EX21:5859ed2a6cb6EX21:5859ed2a6cb6Subsidiarie97%
EX21:5a0d19bd4c6cEX21:5a0d19bd4c6cSubsidiarie97%
EX21:5a7daf9c17f1EX21:5a7daf9c17f1Subsidiarie97%
EX21:5b2d1ef0e74fEX21:5b2d1ef0e74fSubsidiarie97%
EX21:5b9b86047bd2EX21:5b9b86047bd2Subsidiarie97%
EX21:5bb481cea935EX21:5bb481cea935Subsidiarie97%
EX21:5c1ee301cb1cEX21:5c1ee301cb1cSubsidiarie97%
EX21:5c384aaf75fbEX21:5c384aaf75fbSubsidiarie97%
EX21:5c71ac8f4c9eEX21:5c71ac8f4c9eSubsidiarie97%
EX21:5ca02b31e108EX21:5ca02b31e108Subsidiarie97%
EX21:5d507df34374EX21:5d507df34374Subsidiarie97%
EX21:5ed3a56aca77EX21:5ed3a56aca77Subsidiarie97%
EX21:5fa14b5cf0bfEX21:5fa14b5cf0bfSubsidiarie97%
EX21:600f30225468EX21:600f30225468Subsidiarie97%
EX21:62684aa02b4fEX21:62684aa02b4fSubsidiarie97%
EX21:6279200c0022EX21:6279200c0022Subsidiarie97%
EX21:6520e27eeb9bEX21:6520e27eeb9bSubsidiarie97%
EX21:654588fd2651EX21:654588fd2651Subsidiarie97%
EX21:659dfc080c6aEX21:659dfc080c6aSubsidiarie97%
EX21:65e516134a57EX21:65e516134a57Subsidiarie97%
EX21:65edcd0ca788EX21:65edcd0ca788Subsidiarie97%
EX21:6710cf936fd8EX21:6710cf936fd8Subsidiarie97%
EX21:682dba5c9903EX21:682dba5c9903Subsidiarie97%
EX21:68f8b9695c5eEX21:68f8b9695c5eSubsidiarie97%
EX21:69d9f7657d4aEX21:69d9f7657d4aSubsidiarie97%
EX21:6a5b4dcf805bEX21:6a5b4dcf805bSubsidiarie97%
EX21:6b081d00ee13EX21:6b081d00ee13Subsidiarie97%
EX21:6ced43794bc1EX21:6ced43794bc1Subsidiarie97%
EX21:6de3bc507ed3EX21:6de3bc507ed3Subsidiarie97%
EX21:6ef586320434EX21:6ef586320434Subsidiarie97%
EX21:6f66e517c503EX21:6f66e517c503Subsidiarie97%
EX21:71007a2c35e0EX21:71007a2c35e0Subsidiarie97%
EX21:71067b369115EX21:71067b369115Subsidiarie97%
EX21:7143ad168371EX21:7143ad168371Subsidiarie97%
EX21:71b2d3f24bc3EX21:71b2d3f24bc3Subsidiarie97%
EX21:724d8095f368EX21:724d8095f368Subsidiarie97%
EX21:72c967b1041cEX21:72c967b1041cSubsidiarie97%
EX21:7308d56da3d0EX21:7308d56da3d0Subsidiarie97%
EX21:7a2765085685EX21:7a2765085685Subsidiarie97%
EX21:7a311e7e83aaEX21:7a311e7e83aaSubsidiarie97%
EX21:7ba1fe0f73f1EX21:7ba1fe0f73f1Subsidiarie97%
EX21:7c773e44ba47EX21:7c773e44ba47Subsidiarie97%
EX21:7eb683b22d83EX21:7eb683b22d83Subsidiarie97%
EX21:7f4f982e6551EX21:7f4f982e6551Subsidiarie97%
EX21:80a91a24a706EX21:80a91a24a706Subsidiarie97%
EX21:80e2696bf8f3EX21:80e2696bf8f3Subsidiarie97%
EX21:81780d8db727EX21:81780d8db727Subsidiarie97%
EX21:81c2bc0ccff9EX21:81c2bc0ccff9Subsidiarie97%
EX21:82459e007696EX21:82459e007696Subsidiarie97%
EX21:824945a0087dEX21:824945a0087dSubsidiarie97%
EX21:83bdd6e1c7adEX21:83bdd6e1c7adSubsidiarie97%
EX21:84d60aece532EX21:84d60aece532Subsidiarie97%
EX21:86413c4895bcEX21:86413c4895bcSubsidiarie97%
EX21:864cea88cea0EX21:864cea88cea0Subsidiarie97%
EX21:8656ca1c1a7cEX21:8656ca1c1a7cSubsidiarie97%
EX21:87224fd94923EX21:87224fd94923Subsidiarie97%
EX21:874217da0f84EX21:874217da0f84Subsidiarie97%
EX21:89f483349783EX21:89f483349783Subsidiarie97%
EX21:8ceeeb0d0c31EX21:8ceeeb0d0c31Subsidiarie97%
EX21:8cf4e0fdb9aaEX21:8cf4e0fdb9aaSubsidiarie97%
EX21:8e4aee01713fEX21:8e4aee01713fSubsidiarie97%
EX21:91575a671386EX21:91575a671386Subsidiarie97%
EX21:91c014b17b95EX21:91c014b17b95Subsidiarie97%
EX21:91c3927e0896EX21:91c3927e0896Subsidiarie97%
EX21:938802d8995dEX21:938802d8995dSubsidiarie97%
EX21:94c411ecd035EX21:94c411ecd035Subsidiarie97%
EX21:96126c8f40f5EX21:96126c8f40f5Subsidiarie97%
EX21:96457e1eff45EX21:96457e1eff45Subsidiarie97%
EX21:967e2ccaa554EX21:967e2ccaa554Subsidiarie97%
EX21:968d9cb87a83EX21:968d9cb87a83Subsidiarie97%
EX21:977ab841bb40EX21:977ab841bb40Subsidiarie97%
EX21:9839d03c7167EX21:9839d03c7167Subsidiarie97%
EX21:988a2f8a4feeEX21:988a2f8a4feeSubsidiarie97%
EX21:990dca6d820bEX21:990dca6d820bSubsidiarie97%
EX21:99433237f9f4EX21:99433237f9f4Subsidiarie97%
EX21:99556d1ffa20EX21:99556d1ffa20Subsidiarie97%
EX21:9a62951aea19EX21:9a62951aea19Subsidiarie97%
EX21:9b0e4386be8cEX21:9b0e4386be8cSubsidiarie97%
EX21:9becbe279643EX21:9becbe279643Subsidiarie97%
EX21:9c49a5624aaaEX21:9c49a5624aaaSubsidiarie97%
EX21:9cb074ad9fa4EX21:9cb074ad9fa4Subsidiarie97%
EX21:9d0f3b32f161EX21:9d0f3b32f161Subsidiarie97%
EX21:9dac159afd48EX21:9dac159afd48Subsidiarie97%
EX21:9f9d7fa9e5c6EX21:9f9d7fa9e5c6Subsidiarie97%
EX21:a0cc48f67622EX21:a0cc48f67622Subsidiarie97%
EX21:a0d8335e3b24EX21:a0d8335e3b24Subsidiarie97%
EX21:a4a7b8fe1bdbEX21:a4a7b8fe1bdbSubsidiarie97%
EX21:a62437b3e4b4EX21:a62437b3e4b4Subsidiarie97%
EX21:a62e109f271cEX21:a62e109f271cSubsidiarie97%
EX21:a64117dbdfc4EX21:a64117dbdfc4Subsidiarie97%
EX21:a64bfc2496b7EX21:a64bfc2496b7Subsidiarie97%
EX21:a69067d07f5fEX21:a69067d07f5fSubsidiarie97%
EX21:a6c22925ee67EX21:a6c22925ee67Subsidiarie97%
EX21:a7e9d9a38165EX21:a7e9d9a38165Subsidiarie97%
EX21:a81ba4c5570aEX21:a81ba4c5570aSubsidiarie97%
EX21:a875da50c21eEX21:a875da50c21eSubsidiarie97%
EX21:a8e43f6978b6EX21:a8e43f6978b6Subsidiarie97%
EX21:aa4ee5533b14EX21:aa4ee5533b14Subsidiarie97%
EX21:aa96fa33eb7fEX21:aa96fa33eb7fSubsidiarie97%
EX21:ab16d9fd5d0aEX21:ab16d9fd5d0aSubsidiarie97%
EX21:aba41ca55cefEX21:aba41ca55cefSubsidiarie97%
EX21:abe3d479768aEX21:abe3d479768aSubsidiarie97%
EX21:aede32849c00EX21:aede32849c00Subsidiarie97%
EX21:b02d7df24b9cEX21:b02d7df24b9cSubsidiarie97%
EX21:b0eff5d9072fEX21:b0eff5d9072fSubsidiarie97%
EX21:b11cf60d17fbEX21:b11cf60d17fbSubsidiarie97%
EX21:b2595afc411dEX21:b2595afc411dSubsidiarie97%
EX21:b3ec765bc9fbEX21:b3ec765bc9fbSubsidiarie97%
EX21:b4c34dc5abd6EX21:b4c34dc5abd6Subsidiarie97%
EX21:b56a707223e1EX21:b56a707223e1Subsidiarie97%
EX21:b59b9e27715dEX21:b59b9e27715dSubsidiarie97%
EX21:b8182f9ed9d0EX21:b8182f9ed9d0Subsidiarie97%
EX21:b9420ae92050EX21:b9420ae92050Subsidiarie97%
EX21:b94e62e1a0a8EX21:b94e62e1a0a8Subsidiarie97%
EX21:bdd89fb5b0ebEX21:bdd89fb5b0ebSubsidiarie97%
EX21:be5f1d15e550EX21:be5f1d15e550Subsidiarie97%
EX21:c02a208f68edEX21:c02a208f68edSubsidiarie97%
EX21:c0809e791c40EX21:c0809e791c40Subsidiarie97%
EX21:c0c26c965792EX21:c0c26c965792Subsidiarie97%
EX21:c14655077b8fEX21:c14655077b8fSubsidiarie97%
EX21:c1b805706dd0EX21:c1b805706dd0Subsidiarie97%
EX21:c35d53ac808eEX21:c35d53ac808eSubsidiarie97%
EX21:c3db7e5abf0eEX21:c3db7e5abf0eSubsidiarie97%
EX21:c527461a33daEX21:c527461a33daSubsidiarie97%
EX21:c5b529dd2a74EX21:c5b529dd2a74Subsidiarie97%
EX21:c671ae077945EX21:c671ae077945Subsidiarie97%
EX21:c6bd2cefd354EX21:c6bd2cefd354Subsidiarie97%
EX21:c7e90b478ef8EX21:c7e90b478ef8Subsidiarie97%
EX21:cba52e2ea777EX21:cba52e2ea777Subsidiarie97%
EX21:cbbdddcbcacbEX21:cbbdddcbcacbSubsidiarie97%
EX21:cc3f1bb17f0aEX21:cc3f1bb17f0aSubsidiarie97%
EX21:cd320d2b7b54EX21:cd320d2b7b54Subsidiarie97%
EX21:cdae65100df5EX21:cdae65100df5Subsidiarie97%
EX21:cdf920576de8EX21:cdf920576de8Subsidiarie97%
EX21:d0011a600bd6EX21:d0011a600bd6Subsidiarie97%
EX21:d27eb3eb6251EX21:d27eb3eb6251Subsidiarie97%
EX21:d7f926bb19a6EX21:d7f926bb19a6Subsidiarie97%
EX21:d82f591f57ceEX21:d82f591f57ceSubsidiarie97%
EX21:d899e5daaa10EX21:d899e5daaa10Subsidiarie97%
EX21:d8c33670f5f0EX21:d8c33670f5f0Subsidiarie97%
EX21:da2b67af6523EX21:da2b67af6523Subsidiarie97%
EX21:dc3396a5f5f3EX21:dc3396a5f5f3Subsidiarie97%
EX21:dd95c95d4227EX21:dd95c95d4227Subsidiarie97%
EX21:e4047526e1ffEX21:e4047526e1ffSubsidiarie97%
EX21:e44c4d8fe0d4EX21:e44c4d8fe0d4Subsidiarie97%
EX21:e44f1b86ba21EX21:e44f1b86ba21Subsidiarie97%
EX21:e4a1f907de6eEX21:e4a1f907de6eSubsidiarie97%
EX21:e616da740679EX21:e616da740679Subsidiarie97%
EX21:e636531a1182EX21:e636531a1182Subsidiarie97%
EX21:e69c0681cb1eEX21:e69c0681cb1eSubsidiarie97%
EX21:e801b4ae8131EX21:e801b4ae8131Subsidiarie97%
EX21:e81dfe69841aEX21:e81dfe69841aSubsidiarie97%
EX21:e895cf30367bEX21:e895cf30367bSubsidiarie97%
EX21:ea228b7c8a34EX21:ea228b7c8a34Subsidiarie97%
EX21:eaf984c09e0aEX21:eaf984c09e0aSubsidiarie97%
EX21:ebaeb540d5a9EX21:ebaeb540d5a9Subsidiarie97%
EX21:ec26a36ec3cfEX21:ec26a36ec3cfSubsidiarie97%
EX21:edfab7b6cd5dEX21:edfab7b6cd5dSubsidiarie97%
EX21:ee865f1d0fa9EX21:ee865f1d0fa9Subsidiarie97%
EX21:ef6e006968d6EX21:ef6e006968d6Subsidiarie97%
EX21:f02eb1c5553aEX21:f02eb1c5553aSubsidiarie97%
EX21:f2ca2920da81EX21:f2ca2920da81Subsidiarie97%
EX21:f35835b3c2b7EX21:f35835b3c2b7Subsidiarie97%
EX21:f59f21d2add2EX21:f59f21d2add2Subsidiarie97%
EX21:f5ed3b4da851EX21:f5ed3b4da851Subsidiarie97%
EX21:f6fff6dae60aEX21:f6fff6dae60aSubsidiarie97%
EX21:f7658a74a7cbEX21:f7658a74a7cbSubsidiarie97%
EX21:f78a7a82c657EX21:f78a7a82c657Subsidiarie97%
EX21:f8ed04caa070EX21:f8ed04caa070Subsidiarie97%
EX21:f9e9067073a8EX21:f9e9067073a8Subsidiarie97%
EX21:fc43c6f8315cEX21:fc43c6f8315cSubsidiarie97%
EX21:fd84680fb0feEX21:fd84680fb0feSubsidiarie97%
EX21:ffa43c62299cEX21:ffa43c62299cSubsidiarie97%
Supply chain
— missing data
Peer comparison
Peer comparison7 peers · vs PFE · multiples and returns
JN
JNJ—
Johnson & Johnson
$254,43
622,1B USDP/E
23,5x
+5,3 vs self
Div yield
2,0 %
-4,9 vs self
ROE
33,0 %
+24,4 vs self
LL
LLY—
ELI LILLY AND COMPANY
$1 124,04
1,01T USDP/E
52,0x
+33,8 vs self
Div yield
0,5 %
-6,3 vs self
ROE
66,2 %
+57,5 vs self
MR
MRK—
MERCK & CO., INC.
—
—P/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
AB
ABBV—
Abbvie Inc
$245,10
434,8B USDP/E
110,6x
+92,4 vs self
Div yield
2,5 %
-4,3 vs self
ROE
-63,5 %
-72,1 vs self
AZ
AZN—
AZN.L
$157,59
—P/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
BM
BMY—
Bristol-myers Squibb Co
$65,60
134,3B USDP/E
17,7x
-0,5 vs self
Div yield
4,1 %
-2,8 vs self
ROE
31,6 %
+23,0 vs self
GS
GSK—
Gsk Plc-spon Adr
—
—P/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 69 %
EPS
Consensus EPS
2,96
Predicted surprise
+0,08
Beat probability
69 %
Analysts
32
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
revision ratio 3,35 · as of 2026-05-23 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 2,96 |
| Revenue | —no estimate | —no estimate | 61,8B USD |
| Operating income | —no estimate | —no estimate | 21,9B USD |
Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution32 analysts
Strong buy5
Buy7
Hold18
Sell1
Strong sell1
12-month price target$29,03 · Median $28,00
Low $24,00High $36,00
Operating income · consensus21,9B USD
EPS surprise
+8,9 %
reported vs consensus · beat
Revenue surprise
+1,3 %
reported vs consensus · beat
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$24,00
Mean$28,58
Median$28,00
High$35,46
Spot$25,05
+14.1 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskMedium
Liquidity riskHigh
Filing-based flags
- Current ratio is close to the minimum comfort range.
- Net cash is negative after subtracting total debt.
- Source documents mention dilution or offering risk.
Benchmarks vs cohort
Net Margin12,4 %Above median
ROE8,6 %Above median
Capex / Rev4,2 %Above P75
D/E0,72Bottom quartile
Cash Conv1,51Above median
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 93 774 sh26 grants12 insiders
- Director, Chairman & CEO · Phantom Stock Units SSP → Common StockAcquired 24grant · 2026-07-31
- Director, Chairman & CEO · Phantom Stock Units SSP → Common StockAcquired 24grant · 2026-07-15
- Director, Chairman & CEO · Phantom Stock Units SSP → Common StockAcquired 84grant · 2026-07-09
- Director, Chairman & CEO · Phantom Stock Units SSP → Common StockAcquired 23grant · 2026-06-15
- Director, Chairman & CEO · Phantom Stock Units SSP → Common StockAcquired 23grant · 2026-05-29
- Director, Chairman & CEO · Phantom Stock Units SSP → Common StockAcquired 24grant · 2026-05-15
- Director, Chairman & CEO · Phantom Stock Units SSP → Common StockAcquired 22grant · 2026-04-30
- Director · Phantom Stock Units → Common StockAcquired 7 687grant · 2026-04-23
- Director · Phantom Stock Units → Common StockAcquired 7 687grant · 2026-04-23
- Director · Phantom Stock Units → Common StockAcquired 7 687grant · 2026-04-23
- Director · Phantom Stock Units → Common StockAcquired 7 687grant · 2026-04-23
- Director · Phantom Stock Units → Common StockAcquired 7 687grant · 2026-04-23
- Director · Phantom Stock Units → Common StockAcquired 7 687grant · 2026-04-23
- Director · Phantom Stock Units → Common StockAcquired 7 687grant · 2026-04-23
- Director · Phantom Stock Units → Common StockAcquired 7 687grant · 2026-04-23
- Director · Phantom Stock Units → Common StockAcquired 7 687grant · 2026-04-23
- Director · Phantom Stock Units → Common StockAcquired 7 687grant · 2026-04-23
- Director · Phantom Stock Units → Common StockAcquired 7 687grant · 2026-04-23
- Director, Chairman & CEO · Phantom Stock Units SSP → Common StockAcquired 22grant · 2026-04-15
- Director, Chairman & CEO · Phantom Stock Units SSP → Common StockAcquired 911grant · 2026-04-14
- Director, Chairman & CEO · Phantom Stock Units SSP → Common StockAcquired 21grant · 2026-03-31
- Director · Phantom Stock Units → Common StockAcquired 1 849grant · 2026-03-27
- Director · Phantom Stock Units → Common StockAcquired 1 710grant · 2026-03-27
- Director · Phantom Stock Units → Common StockAcquired 1 387grant · 2026-03-27
- Director · Phantom Stock Units → Common StockAcquired 1 433grant · 2026-03-27
Physical assets
1 tracked| Asset | Type | Commodity | Country | Role |
|---|---|---|---|---|
| Pfizer Groton Plant | Power | Power | US | Operating company |
Tracked physical assets associated with this issuer (operated, managed, or owned).
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Regulatory filings
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
How metrics are computed
- Cash Conversion Ratiooperating_cash_flow / net_income
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Ev To Revenueenterprise_value / revenue
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Market Capmarket_price * shares_outstanding_diluted
Source documents
- PFIZER INC company facts · 2026-08-04
- PFIZER INC 10-Q 2026-05-05 · 2026-08-04
- PFIZER INC 10-K 2026-02-26 · 2026-08-04
- PFIZER INC 10-Q 2025-11-04 · 2026-08-04
- PFIZER INC 10-Q 2025-08-05 · 2026-08-04
- pre_earnings_window (pre_earnings_window) on PFE · 2026-08-04
- Pfizer Inc Market data — analyst estimates · 2026-08-04
- Pfizer Inc Market data — ESG · 2026-08-04
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-311,00 %$2 947M
- Institutional Investor · as of 2026-03-310,54 %$1 619M
- Institutional Investor · as of 2022-09-300,46 %$0M
- Investment Managers · as of 2026-03-310,41 %$573M
- Investment Managers · as of 2026-03-310,29 %$8 469M
- Investment Managers · as of 2026-03-310,28 %$435M
- Institutional Investor · as of 2026-03-310,28 %$1 513M
- Investment Managers · as of 2024-06-300,27 %$11 874M
- Investment Managers · as of 2026-03-310,26 %$1 402M
- Investment Managers · as of 2026-03-310,23 %$3 737M
- Investment Managers · as of 2026-03-310,23 %$1 742M
- Investment Managers · as of 2026-03-310,22 %$1 457M
- Investment Managers · as of 2026-03-310,21 %$1 023M
- Investment Managers · as of 2025-12-310,20 %$13 480M
- Investment Managers · as of 2026-03-310,19 %$796M
- Investment Managers · as of 2026-03-310,17 %$1 323M
- Investment Managers · as of 2026-03-310,16 %$2 603M
- Investment Managers · as of 2026-03-310,15 %$334M
- Institutional Investor · as of 2026-03-310,13 %$548M
- Funds · as of 2026-03-310,12 %$785M
- Investment Managers · as of 2024-12-310,11 %$402M
- Investment Managers · as of 2026-03-310,11 %$196M
- Brokerage Firms · as of 2026-03-310,11 %$548M
- Brokerage Firms · as of 2026-03-310,10 %$328M
- Investment Managers · as of 2026-03-310,10 %$376M
- Investment Managers · as of 2026-03-310,10 %$178M
- Investment Managers · as of 2026-03-310,09 %$494M
- Investment Managers · as of 2026-03-310,08 %$616M
- Institutional Investor · as of 2026-03-310,06 %$122M
- Investment Managers · as of 2026-03-310,06 %$174M
- Investment Managers · as of 2026-03-310,05 %$0M
- Institutional Investor · as of 2026-03-310,04 %$91M
- Institutional Investor · as of 2026-03-310,02 %$353M
- Investment Managers · as of 2026-03-310,02 %$31M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$0M
Leadership
- Albert BourlaChairman of the Board, Chief Executive Officer
Insider activity
Net selling0 buys · 1 sellsnet -$51K1 insiders · last 365d
- SVP & Controller · Common StockSold 2 000 @ $25,70$51K · 2026-06-09
Short positioning
163.8Mshares short+0.1% vs prior
3.83days to cover
46.7%short of daily vol
4.6Kfails-to-deliver
as of 2026-07-15 · short-interest report (free)
Index membership
S&P 500United States
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
PFECanonical
NYSE · USD
Intel & risk
What changed
no material change vs prior analysis (walked 17 fields; 4 schema-expansion field(s) excluded)
- Company share pct— → —medium
vs prior analysis 1 day ago
peak dispatch · —
OSINT findings
Dilution riskMedium
Liquidity riskHigh
Current ratio is close to the minimum comfort range.
Net cash is negative after subtracting total debt.
Source documents mention dilution or offering risk.
Relationship graph
This companySectorSubsidiaries
Evidence & claims
From filings & derived data- Return on equity (FY 2025-12-31): 9.0%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -3.5%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 9.5%Derived (calculated)
- Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): -10.0%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -2.8%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): -2.5%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -2.0%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): -1.6%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -8.2%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): -3.2%Derived (calculated)
- Long-term debt (YoY) (2025-12-31 vs 2024-12-31): 7.4%Derived (calculated)
- Net margin (FY 2025-12-31): 12.4%Derived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): -9.6%Derived (calculated)
- Return on assets (FY 2025-12-31): 3.7%Derived (calculated)
- Current ratio (FY 2025-12-31): 1.16xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 1.40xDerived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -3.5%Derived (calculated)
- Current assets (annual): USD 42.9BSEC XBRL filing
- Cash & equivalents (annual): USD 1.14BSEC XBRL filing
- Current liabilities (annual): USD 36.98BSEC XBRL filing
- Capex (annual): USD 2.63BSEC XBRL filing
- Total liabilities (annual): USD 121.39BSEC XBRL filing
- Revenue (annual): USD 62.58BSEC XBRL filing
- Interest expense (annual): USD 2.67BSEC XBRL filing
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-08-04EVENTUpcomingQ2 2026 earnings (expected) estimated date
2026-08-03 07:40 UTCEVENTEarnings Window
2026-07-15INSIDERBOURLA ALBERT acquired 24 sh Phantom Stock Units SSP — Director, Chairman & CEO
2026-07-09INSIDERBOURLA ALBERT acquired 84 sh Phantom Stock Units SSP — Director, Chairman & CEO
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-06-15 00:00 UTCINSIDER2 insider transactions — 2026-06 1 derivative
2026-06-15INSIDERBOURLA ALBERT acquired 23 sh Phantom Stock Units SSP — Director, Chairman & CEO
2026-06-09INSIDERDAMICO JENNIFER B. sold 2.0k sh — SVP & Controller ~$51k
2026-05-29 00:00 UTCINSIDER2 insider transactions — 2026-05 2 derivative
2026-05-29INSIDERBOURLA ALBERT acquired 23 sh Phantom Stock Units SSP — Director, Chairman & CEO
2026-05-15INSIDERBOURLA ALBERT acquired 24 sh Phantom Stock Units SSP — Director, Chairman & CEO
2026-04-30 00:00 UTCINSIDER14 insider transactions — 2026-04 14 derivative
2026-04-30INSIDERBOURLA ALBERT acquired 22 sh Phantom Stock Units SSP — Director, Chairman & CEO
2026-04-23INSIDERNORA JOHNSON SUZANNE M acquired 7.7k sh Phantom Stock Units — Director
2026-04-23INSIDERGottlieb Scott acquired 7.7k sh Phantom Stock Units — Director
2026-04-23INSIDEREchevarria Joseph acquired 7.7k sh Phantom Stock Units — Director
2026-04-23INSIDERNARAYEN SHANTANU acquired 7.7k sh Phantom Stock Units — Director
2026-04-23INSIDERQuincey James acquired 7.7k sh Phantom Stock Units — Director
2026-04-23INSIDERLITTMAN DAN R. acquired 7.7k sh Phantom Stock Units — Director
2026-04-23INSIDERDesmond-Hellmann Susan acquired 7.7k sh Phantom Stock Units — Director
2026-04-23INSIDERTaraporevala Cyrus acquired 7.7k sh Phantom Stock Units — Director
2026-04-23INSIDERSMITH JAMES C acquired 7.7k sh Phantom Stock Units — Director
Showing the 40 most recent of 89 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data
Premium coverage